These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9166539)

  • 21. Advertising genetic testing for breast cancer.
    Weber LJ; Bissell MG
    Clin Leadersh Manag Rev; 2004; 18(1):50-1. PubMed ID: 14968755
    [No Abstract]   [Full Text] [Related]  

  • 22. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN; Wung SF; Merkle CJ
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women].
    Mestiri S; Monastiri K; Ben Ahmed S; Bouaouina N; Presneau N; Bignon YJ; Khairi H; Chouchane L
    Arch Inst Pasteur Tunis; 2000; 77(1-4):11-5. PubMed ID: 14658222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 27. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
    Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
    Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal selection of individuals for BRCA mutation testing.
    Evans DG; Lalloo F; Eccles D
    J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
    [No Abstract]   [Full Text] [Related]  

  • 29. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
    Loman N
    Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations in genetic counseling for inherited breast cancer predisposition.
    Robson ME; Offit K
    Semin Radiat Oncol; 2002 Oct; 12(4):362-70. PubMed ID: 12382194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
    Grzybowska E; Siemińska M; Zientek H; Kalinowska E; Michalska J; Utracka-Hutka B; Rogozińska-Szczepka J; Kaźmierczak-Maciejewska M
    Acta Biochim Pol; 2002; 49(2):351-6. PubMed ID: 12362976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer: genetics, risks, and strategies.
    Nogueira SM; Appling SE
    Nurs Clin North Am; 2000 Sep; 35(3):663-9. PubMed ID: 10957681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision.
    Friedenson B
    MedGenMed; 2001 Nov; 3(6):2. PubMed ID: 11965197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation analysis of the breast cancer gene BRCA1 among breast cancer Jordanian females.
    Atoum MF; Al-Kayed SA
    Saudi Med J; 2004 Jan; 25(1):60-3. PubMed ID: 14758382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BRCA breast cancer patient: treat the tumor or the problem?
    Zippel D; Papa MZ
    J Surg Oncol; 2008 Jun; 97(7):561-2. PubMed ID: 18302144
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical implications of genetic testing for inherited breast and ovarian cancer risk.
    Calzone KA
    Nurs Spectr (Wash D C); 1998 Nov; 8(23):12-4. PubMed ID: 10542772
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
    Eisinger F; Huiart L
    J Natl Cancer Inst; 2009 Feb; 101(4):277; author reply 277-8. PubMed ID: 19211447
    [No Abstract]   [Full Text] [Related]  

  • 40. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.